PepGen Inc. (NASDAQ:PEPG) is among the best fast money stocks to buy now. H.C. Wainwright has reaffirmed its ‘Buy’ rating on PepGen Inc. (NASDAQ:PEPG), while increasing the price target to $12.00 from $8.00, implying a surge of nearly 135%. This optimism stems from the company’s 53.7% mean splicing correction at 15 mg/kg report in its FREEDOM single-dose study for DM1 patients, showcasing the highest level disclosed in DM1 patients till now. The research firm noted that this nearly 54% splicing correction ...

BOSTON,--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 4,687,500 additional shares, at the public offer. ...

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. PepGen Inc. (NASDAQ:PEPG) is one of the top performers on Thursday. Shares of PepGen soared by 121.05 percent on Thursday to end at $5.88 apiece as investors cheered stellar results from its clinical trial of an experimental drug to treat myotonic dystrophy type 1 (DM1). In a statement, PepGen Inc. (NASDAQ:PEPG) said it saw a 53.7 percent correction in the key genetic error that drives the disease in patients taking 15 mg/kg of t ...

PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.PepGen on Wednesday released clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1).Myotonic dystrophy is a rare, inherited genetic disorder characterized by progressive muscle weakness and myotonia, which is the inabil ...

盘前交易概况 - 美东时间周四上午7:35盘前交易出现显著活跃 多只股票呈现价格异动[1] - 盘前价格变动可能预示开盘后潜在交易机会 包括突破、反转或剧烈波动[1] - 早盘动量通常延续至常规交易时段 使盘前分析成为交易日关键组成部分[1] 涨幅显著股票 - PepGen Inc (PEPG) 股价上涨151%至6.68美元 位列涨幅榜首[3] - 22nd Century Group Inc (XXII) 上涨27%至1.93美元 涨幅排名第二[3] - Immuneering Corporation (IMRX) 上涨23%至11.36美元 位列涨幅第三[3] - uniQure N.V. (QURE) 上涨10%至52.58美元 锂业公司Lithium Americas Corp (LAC)同步上涨9%至6.60美元[3] - Jasper Therapeutics Inc (JSPR) 上涨9%至2.55美元 American Shared Hospital Services (AMS) 上涨8%至2.75美元[3] - PSQ Holdings Inc (PSQH) 上涨7%至3.06美元 K Wave Media Ltd (KWM) 同步上涨7%至2.48美元[3] - ClearPoint Neuro Inc (CLPT) 上涨5%至20.48美元 跻身涨幅前十[3] 跌幅显著股票 - Transocean Ltd (RIG) 下跌14%至3.11美元 领跌盘前交易[4] - Cyclerion Therapeutics Inc (CYCN) 下跌12%至2.83美元 跌幅排名第二[4] - CarMax Inc (KMX) 下跌11%至50.38美元 ARB IOT Group Limited (ARBB) 同步下跌11%至10.45美元[4] - SHF Holdings Inc (SHFS) 下跌10%至6.49美元 Digital Brands Group Inc (DBGI) 同步下跌10%至6.21美元[4] - Aqua Metals Inc (AQMS) 下跌9%至5.29美元 Akanda Corp (AKAN) 下跌8%至3.96美元[4] - Galecto Inc (GLTO) 下跌8%至3.88美元 Platinum Analytics Cayman Limited (PLTS) 下跌7%至11.12美元[4]

Shares of PepGen Inc. PEPG rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.PepGen shares jumped 112.4% to $5.65 in the pre-market trading session.Here are some other stocks moving in pre-market trading.GainersOFA Group OFAL rose 49.6% to $1.99 in pre-market trading after the company announced a partnership with Blockchain App Factory to co-develop a real estate equity and mortgage-backed RWA platform.WORK Me ...

With U.S. stock futures trading mixed this morning on Thursday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Costco Wholesale Corporation COST to report quarterly earnings at $5.80 per share on revenue of $86.11 billion after the closing bell, according to data from Benzinga Pro. Costco shares gained 0.1% to $946.00 in after-hours trading.Stitch Fix Inc SFIX reported better-than-expected fourth-quarter earnings and issued FY2026 guidance above estimates. Stitch Fi ...

PepGen Inc. PEPG shares surged 119.55% to $5.84 during after-hours trading on Wednesday following the clinical-stage company’s announcement of an underwritten public offering. Check out the current price of PEPG stock here. Public Offering Details Drive Market ResponseThe Cambridge, Massachusetts-based biotech has announced the launch of an underwritten public offering of common stock and pre-funded warrants. Leerink Partners and Stifel SF are acting as joint book-running managers for the offering, with the ...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $100 million, before deducting un. ...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being. ...